Nourishes the liver and kidneys, improves blood and essence

Nourishes the liver and kidneys, improves sperm quality and improves eyesight

Nourishes blood and promotes blood circulation, regulates menstruation and relieves pain

Nourishes the liver and kidneys, strengthens the bones and muscles

Diuresis and dampness removal, spleen strengthening and mind calming

Nourishes the kidney and strengthens the essence, nourishes the liver and improves eyesight

Warming the kidney and boosting yang, consolidating semen and reducing urine

Has analgesic effect

Edaravone is a brain protective agent (free radical scavenger) that can scavenge free radicals and inhibit lipid peroxidation, thereby inhibiting oxidative damage to brain cells, vascular endothelial cells, and nerve cells. Clinical studies have shown that edaravone can inhibit the reduction of local cerebral blood flow around the infarction, and the NAA content in the brain on the 28th day after onset is significantly higher than that in the glycerol control group; preclinical studies have shown that intravenous administration of edaravone to rats after ischemia/ischemia-reperfusion can prevent the progression of cerebral edema and cerebral infarction, relieve the accompanying neurological symptoms, and inhibit delayed neuronal death.

The mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of bacterial ribosomes, inhibiting RNA-dependent protein synthesis. It is rapidly absorbed after oral administration, with a bioavailability of 37%. After a single oral dose of 0.5g, the peak time is 2.5 to 2.6 hours, and the peak blood concentration (Cmax) is 0.4 to 0.45 mg/L. This product is widely distributed in the body, and the concentration in various tissues can reach 10 to 100 times the blood concentration in the same period. The concentration in macrophages and fibroblasts is high, and the former can transport azithromycin to the site of inflammation. The blood elimination half-life (t1/2β) of this product after a single dose is 35 to 48 hours, and more than 50% of the dose is excreted in the bile duct in its original form, and about 4.5% is excreted in the urine in its original form within 72 hours after administration. The serum protein binding rate of this product decreases with the increase of blood drug concentration. When the blood drug concentration is 0.02μg/ml, the serum protein binding rate is 15%; when the blood drug concentration is 2μg/ml, the serum protein binding rate is 7%.

Rosuvastatin is a selective and competitive HMG-CoA reductase inhibitor that can increase the number of liver LDL receptors on the cell surface, enhance the uptake and catabolism of LDL, inhibit liver VLDL synthesis, and reduce the total number of VLDL and LDL particles. For patients with various hypercholesterolemia and dyslipidemia, it can reduce total cholesterol, LDL-C, ApoB, non-HDL-C levels, while reducing TG and increasing HDL-C levels.